Arcus Biosciences (RCUS) Profit After Tax (2017 - 2026)

Arcus Biosciences' Profit After Tax history runs 10 years deep, the most recent figure standing at -$128.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 14.29% year-over-year to -$128.0 million; the TTM figure through Mar 2026 stood at -$369.0 million (up 5.63% YoY), while the FY2025 annual figure was -$353.0 million, down 24.73% from the prior year.
• Profit After Tax for Q1 2026 stood at -$128.0 million, down from -$106.0 million in the prior quarter.
• The five-year high for Profit After Tax was -$4.0 million in Q1 2024, with the low at -$135.0 million in Q3 2025.
• The 5-year median for Profit After Tax is -$80.5 million (2023), against an average of -$83.6 million.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 95.0% in 2024, then plunged 2700.0% in 2025.
• Arcus Biosciences' Profit After Tax stood at -$67.0 million in 2022, then dropped by 20.9% to -$81.0 million in 2023, then decreased by 16.05% to -$94.0 million in 2024, then dropped by 12.77% to -$106.0 million in 2025, then slipped by 20.75% to -$128.0 million in 2026.
• Business Quant data shows RCUS's Profit After Tax at -$128.0 million in Q1 2026, -$106.0 million in Q4 2025, and -$135.0 million in Q3 2025.